Development is Risky, Costly, & Stagnant
Stifles Innovation
in the healthcare industry
Unnecessary Risks and Losses
in research and development
Impedes
the creation for patient treatment options
Smart Science Platform
The PHDC Smart Science Platform enables real-time, on-demand test development which saves time and cost in research and development. PHDC is a fully integrated data-to-diagnostic production platform that’s taking the risk out of clinical R&D projects.
- Distribute returns to shareholders
- Validation Both analytical and clinical
- Leverage research and development from others
- IP Protection Patent trade secrets
- Verification CLIA and LDT validation
- Commercialize Create market LDT/FDA
From Preliminary Launch to FDA Approval
Smart Diabetes
Diabetes Prevent is more than a pioneering risk evaluation genetic test. It aims to help you control and prevent type 2 diabetes.
Smart Path
Rapid Slide-Free Pathology Instrument with Potential to Fundamentally Improve Diagnostic Microscopy.
Smart VascularDX
Endothelial Damage in Arteries & Guide Therapy. 2.5x More Sensitive than hsCRP for Inflammation.
Smart KidneyDX
A biomarker-based algorithm that confirms the diagnosis, grades the tumor, and predicts risk of metastases
Smart LungDX
Molecular Diagnostic with a 93% Sensitivity & 57% Specificity. PHDC will gain clinical validation for this technology with less than $2M in R&D spending, in just 12 months.
Smart CellDX
Cardiovascular Disease (CVD) tests currently lack specificity with only cholesterol and lipid panel results
Heart Attack Prevention with PULS
What Patients Say About Us
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
News & Media
Muse Microscopy, Inc. to Present SmartPath MUSE Technology™ (SmartPath) at Upcoming Emerging Medtech Summit (LSI USA ’24) in Dana Point, CA
IRVINE, Calif., March 6, 2024 /PRNewswire/ — Muse Microscopy, Inc., a wholly-owned subsidiary of Smart Health Diagnostics Company, is developing a slide-free diagnostic imaging platform designed to transform the patient’s experience by providing the ability to generate digital tissue images within minutes to send to the pathologist for an immediate read. Larry Dentice, the President and Director […]
SmartPath Dx is Changing Pathology Image by Image, Minute by Minute – SmartHealth Dx announces the unveiling of SmartPath Dx at Octane’s Medical Innovation Forum
IRVINE, Calif., October 25, 2023 /PRNewswire/ — Smart Health Diagnostics Company (“SHDx” or “the Company”), a developer of precision diagnostic tests and imaging technologies that address unmet clinical needs for advancing today’s standards of care, today announced its upcoming participation in Octane’s Medical Innovation Forum 2023 to discuss SmartPath Dx’s impact on human health in the pathology […]
SmartHealth Dx Featured in Cover Story of Med Tech Outlook Magazine’s Pathology Special Edition
IRVINE, Calif., June 13, 2023 /PRNewswire/ — Smart Health Diagnostics Company (“SHDx” or “the Company”), a developer of precision diagnostic tests that address unmet clinical needs in pathology and vascular inflammation for advancing today’s standards of care, announced that CEO and Chairman Mitch Levine is featured in the June 8, 2023 edition of Med Tech […]
SmartHealth Diagnostics Appoints Accomplished Corporate and Finance Leader Mitch Levine as President, Chief Financial Officer, and Director
Highly regarded diagnostics industry executive and capital markets expert to guide planned growth and value creation for evolutionary data-to-diagnostics platform company